GlassScriptPhysician profile
Amer B Nouh
NPI 1952587503
$8,255.42
in general payments reported to CMS, 2019-2025
42 companies · $1,390 in 2025
The $1,390 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,029 · 2020: $526 · 2021: $1,344 · 2022: $1,576 · 2023: $1,367 · 2024: $1,024 · 2025: $1,390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,693 · Education: $87.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,693.48 |
| Education | $87.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,086.86 | 2020-2025 | Relistor |
| Abbvie INC. | $834.37 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $775.37 | 2021-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Collegium Pharmaceutical, INC. | $625.37 | 2020-2025 | Belbuca |
| Pfizer INC. | $588.90 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $493.04 | 2022 | |
| Amgen INC. | $482.78 | 2019-2022 | |
| Sk Life Science, INC. | $476.98 | 2021-2025 | |
| Scilex Pharmaceuticals INC. | $320.11 | 2019-2023 | Ztlido |
| Lilly USA, LLC | $289.26 | 2019-2024 | Emgality, Reyvow |
| Ibsa Pharma INC. | $240.99 | 2023-2025 | Licart, Tirosint, Tirosint |
| Supernus Pharmaceuticals, INC. | $214.85 | 2019-2021 | |
| Allergan, INC. | $162.60 | 2020-2022 | |
| Biodelivery Sciences International, INC. | $157.79 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $147.97 | 2021 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amer Nouh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.